Form 4: Gilead Sciences CFO Andrew Dickinson Reports Stock Transactions
SEC Form 4 Filing
Andrew Dickinson, CFO of Gilead Sciences, reports the vesting and subsequent sale of restricted stock units.
Summary
- On September 10, 2024, Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc., engaged in transactions involving the company's common stock.
- Dickinson vested 3,641 shares of common stock through the vesting of restricted stock units.
- He then sold 1,682 shares of common stock at a price of $81.44 per share to cover tax obligations.
- Following these transactions, Dickinson directly owns 138,919 shares of Gilead Sciences common stock and 39,127 restricted stock units.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document simply reports required insider trading activity related to vesting of stock options and tax obligations.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.
Stakeholder Impact
- The transactions have a minimal impact on stakeholders as they represent routine insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 09/10/2024 | Date of stock vesting and sale transactions. |
| 09/11/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.